All In Biotech

Drug Trial Radar · NCT04397263

A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

A Phase 3, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

38

Actual

Start

Jun 10, 2020

Primary completion

Feb 29, 2024

Study completion Sep 12, 2025

Sponsor

Lead sponsor
Janssen Pharmaceutical K.K.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
May 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety of Guselkumab in participants with Crohn's disease.

Conditions

  • Crohns Disease

Interventions

  • GuselkumabDrug

    Guselkumab will be administered intravenously for the first 3 doses and then subcutaneously for the subsequent doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From baseline (Week 0) up to Week 48
  2. Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)Time frame: From baseline (Week 0) up to Week 48
  3. Number of Participants With Treatment-emergent Adverse Events of Special Interest (TEAESI)Time frame: From baseline (Week 0) up to Week 48
  4. Number of Participants With Treatment-emergent Abnormalities in Hematology Laboratory ParametersTime frame: From baseline (Week 0) up to Week 48
  5. Number of Participants With Treatment-emergent Abnormalities in Chemistry Laboratory ParametersTime frame: From baseline (Week 0) up to Week 48
  6. Number of Participants With TEAEs of InfectionsTime frame: From baseline (Week 0) up to Week 48
  7. Number of Participants With TEAEs of Injection-site ReactionsTime frame: From baseline (Week 0) up to Week 48
  8. Number of Participants With TEAEs Temporally Associated With InfusionTime frame: From baseline (Week 0) up to Week 48
  9. Number of Participants With TEAEs of Suicidal Ideation, Suicidal Behavior, or Self-Injurious Behavior Without Suicidal IntentTime frame: From baseline (Week 0) up to Week 48
  10. Number of Participants With Clinically Significant Treatment-emergent Abnormalities in Vital SignsTime frame: From baseline (Week 0) up to Week 48
  11. Number of Participants With Concomitant Medications for Crohn's DiseaseTime frame: From screening (Week -8) up to Week 48

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • KOKIKAI Tokatsu Tsujinaka Hospital

    Abiko, Japan

  • Institute of Science Tokyo Hospital

    Bunkyō City, Japan

  • Hitachi General Hospital

    Hitachi, Japan

  • Asahikawa Medical University Hospital

    Hokkaido, Japan

  • Ofuna Chuo Hospital

    Kamakura, Japan

  • Kishiwada Tokushukai Hospital

    Kishiwada, Japan

  • Kumamoto University Hospital

    Kumamoto, Japan

  • Japanese Red Cross Kumamoto Hospital

    Kumamoto, Japan

  • Kyorin University Hospital

    Mitaka, Japan

  • Kenseikai Dongo Hospital

    Nara, Japan

  • Hyogo Medical University Hospital

    Nishinomiya Shi, Japan

  • Ishida Clinic of IBD and Gastroenterology

    Ōita, Japan

  • Okayama University Hospital

    Okayama, Japan

  • Saga University Hospital

    Saga, Japan

  • Kitasato University Hospital

    Sagamihara, Japan

  • Saitama Medical Center

    Saitama, Japan

  • Sapporo Tokushukai Hospital

    Sapporo, Japan

  • Sendai Kosei Hospital

    Sendai Miyagi, Japan

  • Jichi Medical University Hospital

    Shimotsuke, Japan

  • National Center for Global Health and Medicine

    Shinjuku- Ku, Japan

  • Tokyo Women's Medical University Hospital

    Shinjuku-ku, Japan

  • Tokyo Metropolitan Bokutoh Hospital

    Sumida Ku, Japan

  • Osaka Medical and Pharmaceutical University Hospital

    Takatsuki, Japan

  • Toyama Prefectural Central Hospital

    Toyama, Japan

  • National Hospital Organization Toyohashi Medical Center

    Toyohashi, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.